Effect of prior therapy and bone marrow metastases on progenitor cell content of blood stem cell harvests in breast cancer patients.
This study was designed to examine the relationship of prior therapy, bone marrow metastases, mobilization, and blood progenitor/stem cell (BSC) collection in breast cancer patients. Cells were collected from 19 breast cancer patients during steady state (nonmobilized group) and from 69 breast cancer patients after cytokine administration (mobilized group). Characteristics of the patients were compared with the cells obtained. A significant inverse association was found between the number of chemotherapy regimens the patients had received prior to BSC collection and the mononuclear cell (MNC) count of the product per liter of blood processed (LBP) with apheresis (P = .0006) and the granulocyte monocyte/macrophage colony-forming cell (GM-CFC) numbers per LBP (P = .0002). This association was evident in both mobilized and nonmobilized patients. Similar results were seen in those 25 patients who had received prior radiation therapy (MNC/LBP, P = .0003; GM-CFC/LBP, P = .0004). Patients in both the mobilized and nonmobilized groups with marrow metastases at the time of collection also had significantly lower levels of MNC/LBP (P = .0039) and GM-CFC/LBP (P = .0001) than did those without marrow metastases. The findings suggest that prior administration of radiation therapy and/or chemotherapy and the presence of marrow metastases all negatively impacted the collection of mobilized and nonmobilized progenitor cells from breast cancer patients. The mechanisms of this impact are not understood.
Demirkazik
Ahmet
A
Department of Internal Medicine, University of Ankara, Turkey.
Kessinger
Anne
A
Lynch
James
J
Reed
Elizabeth
E
Tarantolo
Stefano
S
Sharp
J Graham
JG
D000328:Adult; D001781:Blood Component Removal / Q000592:standards*; D019046:Bone Marrow Neoplasms / Q000209:etiology / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D002452:Cell Count; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007963:Leukocytes, Mononuclear; D008875:Middle Aged; D023461:Myeloid Progenitor Cells; D012189:Retrospective Studies